Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

TRPS1 regulates oestrogen receptor binding and histone acetylation at enhancers

Oncogene volume 37, pages 5281–5291 (2018)Cite this article

Subjects

Abstract

The chromatin state is finely tuned to regulate function and specificity for transcription factors such as oestrogen receptor alpha (ER), which contributes to cell growth in breast cancer. ER transcriptional potential is mediated, in large part, by the specific associated proteins and co-factors that interact with it. Despite the identification and characterisation of several ER coregulators, a complete and systematic view of ER-regulating chromatin modifiers is lacking. By exploiting a focused siRNA screen that investigated the requirement for a library of 330 chromatin regulators in ER-mediated cell growth, we find that the NuRD and coREST histone deacetylation complexes are critical for breast cancer cell proliferation. Further, by proteomic and genomics approaches, we discover the transcription factor TRPS1 to be a key interactor of the NuRD and coREST complexes. Interestingly, TRPS1 gene amplification occurs in 28% of human breast tumours and is associated with poor prognosis. We propose that TRPS1 is required to repress spurious binding of ER, where it contributes to the removal of histone acetylation. Our data suggest that TRPS1 is an important ER-associated transcriptional repressor that regulates cell proliferation, chromatin acetylation and ER binding at the chromatin of cis-regulatory elements.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Johnston SRD, Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer. 2003;3:821–31.

    Article  CAS  PubMed  Google Scholar 

  2. Thomas C, Gustafsson J-Å. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 2011;11:597–608.

    Article  CAS  PubMed  Google Scholar 

  3. Thomas C, Gustafsson J-Å. Progesterone receptor-estrogen receptor crosstalk: a novel insight. Trends Endocrinol Metab. 2015;26:453–4.

    Article  CAS  PubMed  Google Scholar 

  4. Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2011;17:330–9.

    Article  CAS  PubMed  Google Scholar 

  5. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150:12–27.

    Article  CAS  PubMed  Google Scholar 

  6. Jozwik KM, Carroll JS. Pioneer factors in hormone-dependent cancers. Nat Rev Cancer. 2012;12:381–5.

    Article  CAS  PubMed  Google Scholar 

  7. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR, Ali S, Chin S-F, Palmieri C, Caldas C, Carroll JS. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature. 2012;481:389–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R, Lichter P. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet. 2013;14:765–80.

    Article  CAS  PubMed  Google Scholar 

  9. Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, METABRIC Group, Langerød A, Green A, Provenzano E, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Jozwik KM, Chernukhin I, Serandour AA, Nagarajan S, Carroll JS. FOXA1 directs H3K4 monomethylation at enhancers via recruitment of the methyltransferase MLL3. Cell Rep. 2016;17:2715–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Serandour AA, Avner S, Percevault F, Demay F, Bizot M, Lucchetti-Miganeh C, Barloy-Hubler F, Brown M, Lupien M, Métivier R, Salbert G, Eeckhoute J. Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers. Genome Res. 2011;21:555–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Belandia B, Orford RL, Hurst HC, Parker MG. Targeting of SWI/SNF chromatin remodelling complexes to estrogen-responsive genes. EMBO J. 2002;21:4094–103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. DiRenzo J, Shang Y, Phelan M, Sif S, Myers M, Kingston R, Brown M. BRG-1 is recruited to estrogen-responsive promoters and cooperates with factors involved in histone acetylation. Mol Cell Biol. 2000;20:7541–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Hohmann AF, Vakoc CR. A rationale to target the SWI/SNF complex for cancer therapy. Trends Genet. 2014;30:356–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Helin K, Dhanak D. Chromatin proteins and modifications as drug targets. Nature. 2013;502:480–8.

    Article  CAS  PubMed  Google Scholar 

  16. Fortunati N, Bertino S, Costantino L, De Bortoli M, Compagnone A, Bandino A, Catalano MG, Boccuzzi G. Valproic acid restores ER alpha and antiestrogen sensitivity to ER alpha-negative breast cancer cells. Mol Cell Endocrinol. 2010;314:17–22.

    Article  CAS  PubMed  Google Scholar 

  17. Alluri PG, Asangani IA, Chinnaiyan AM. BETs abet Tam-R in ER-positive breast cancer. Cell Res. 2014;24:899–900.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Ladd B, Mazzola AM, Bihani T, Lai Z, Bradford J, Collins M, Barry E, Goeppert AU, Weir HM, Hearne K, Renshaw JG, Mohseni M, Hurt E, Jalla S, Bao H, Hollingsworth R, Reimer C, Zinda M, Fawell S, D’Cruz CM. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations. Oncotarget. 2016;7:54120–36.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Huh SJ, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover DG, Ekram MB, Peluffo G, Brown J, D’Santos C, Krop IE, Dillon D, et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016;529:413–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Mohammed H, D’Santos C, Serandour AA, Ali HR, Brown GD, Atkins A, Rueda OM, Holmes KA, Theodorou V, Robinson JLL, Zwart W, Saadi A, Ross-Innes CS, Chin S-F, Menon S, Stingl J, Palmieri C, Caldas C, Carroll JS. Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep. 2013;3:342–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Mulder KW, Wang X, Escriu C, Ito Y, Schwarz RF, Gillis J, Sirokmány G, Donati G, Uribe-Lewis S, Pavlidis P, Murrell A, Markowetz F, Watt FM. Diverse epigenetic strategies interact to control epidermal differentiation. Nat Cell Biol. 2012;14:753–63.

    Article  CAS  PubMed  Google Scholar 

  22. Kawai H, Li H, Chun P, Avraham S, Avraham HK. Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene. 2002;21:7730–9.

    Article  CAS  PubMed  Google Scholar 

  23. Nagarajan S, Hossan T, Alawi M, Najafova Z, Indenbirken D, Bedi U, Taipaleenmäki H, Ben-Batalla I, Scheller M, Loges S, Knapp S, Hesse E, Chiang C-M, Grundhoff A, Johnsen SA. Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcription. Cell Rep. 2014;8:460–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Toska E, Osmanbeyoglu HU, Castel P, Chan C, Hendrickson RC, Elkabets M, Dickler MN, Scaltriti M, Leslie CS, Armstrong SA, Baselga J. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science. 2017;355:1324–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Mohammed H, Taylor C, Brown GD, Papachristou EK, Carroll JS, D’Santos CS. Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) for analysis of chromatin complexes. Nat Protoc. 2016;11:316–26.

    Article  CAS  PubMed  Google Scholar 

  26. Theodorou V, Stark R, Menon S, Carroll JS. GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility. Genome Res. 2013;23:12–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Eeckhoute J, Keeton EK, Lupien M, Krum SA, Carroll JS, Brown M. Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Res. 2007;67:6477–83.

    Article  CAS  PubMed  Google Scholar 

  28. Perdomo J, Crossley M. The Ikaros family protein Eos associates with C-terminal-binding protein corepressors. Eur J Biochem. 2002;269:5885–92.

    Article  CAS  PubMed  Google Scholar 

  29. Wu L, Wang Y, Liu Y, Yu S, Xie H, Shi X, Qin S, Ma F, Tan TZ, Thiery JP, Chen L. A central role for TRPS1 in the control of cell cycle and cancer development. Oncotarget. 2014;5:7677–90.

    PubMed  PubMed Central  Google Scholar 

  30. Chen JQ, Bao Y, Litton J, Xiao L, Zhang H-Z, Warneke CL, Wu Y, Shen X, Wu S, Katz RL, Sahin A, Bondy M, Murray JL, Radvanyi L. Expression and relevance of TRPS-1: a new GATA transcription factor in breast cancer. Horm Cancer. 2011;2:132–43.

    Article  CAS  PubMed  Google Scholar 

  31. Sanchez-Garcia FL, Villagrasa P, Matsui J, Kotliar D, Castro VN, Akavia U-D, Chen B-J, Saucedo-Cuevas L, Rodriguez Barrueco R, Llobet-Navas D, Silva JM, Pe er D. Integration of genomic data enables selective discovery of breast cancer drivers. Cell. 2014;159:1461–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet. 2011;43:27–33.

    Article  CAS  PubMed  Google Scholar 

  33. Kurihara I, Lee D-K, Petit FG, Jeong J, Lee K, Lydon JP, DeMayo FJ, Tsai M-J, Tsai SY. COUP-TFII mediates progesterone regulation of uterine implantation by controlling ER activity. PLoS Genet. 2007;3:e102.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W, Liu XS. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008;9:R137.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Perissi V, Jepsen K, Glass CK, Rosenfeld MG. Deconstructing repression: evolving models of co-repressor action. Nat Rev Genet. 2010;11:109–23.

    Article  CAS  PubMed  Google Scholar 

  36. Cerase A, Pintacuda G, Tattermusch A, Avner P. Xist localization and function: new insights from multiple levels. Genome Biol. 2015;16:166.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Schmidt D, Wilson MD, Spyrou C, Brown GD, Hadfield J, Odom DT. ScChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. Methods. 2009;48:240–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Ross-Innes CS, Stark R, Holmes KA, Schmidt D, Spyrou C, Russell R, Massie CE, Vowler SL, Eldridge M, Carroll JS. Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Genes Dev. 2010;24:171–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Wang S, Sun H, Ma J, Zang C, Wang C, Wang J, Tang Q, Meyer CA, Zhang Y, Liu XS. Target analysis by integration of transcriptome and ChIP-seq data with BETA. Nature protocols. 2013;8:2502–2515.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We would like to thank Clive D’Santos and Chris Taylor from the CRUK CI Proteomics core, James Hadfield and the other members of the Genomics core, and Suraj Menon from the Bioinformatics core. Jason Carroll is supported by an ERC Consolidator grant and a Komen Scholar Award. We would like to acknowledge the support of the University of Cambridge, Cancer Research UK and Hutchison Whampoa Limited.

Author contributions

AAS, HM, KWM and JSC designed the project and wrote the manuscript. AAS, HM and AM performed the experiments and analysed the data.

Author information

Authors and Affiliations

  1. Cambridge Institute, Cancer Research UK, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK

    A. A. Serandour, H. Mohammed, A. Miremadi, K. W. Mulder & J. S. Carroll

  2. CRCINA, INSERM, CNRS, Université d’Angers, Université de Nantes; Ecole Centrale de Nantes, Nantes, France

    A. A. Serandour

  3. Knight Cancer Early Detection Advanced Research Center, Oregon Health and Science University, Portland, Oregon, USA

    H. Mohammed

  4. Faculty of Science, Radboud Institute for Molecular Life Sciences, Department of Molecular Developmental Biology, Radboud University, Nijmegen, The Netherlands

    K. W. Mulder

Authors
  1. A. A. Serandour
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Mohammed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Miremadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. W. Mulder
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. S. Carroll
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to K. W. Mulder or J. S. Carroll.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

These authors contributed equally: A.A. Serandour and H. Mohammed.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Serandour, A.A., Mohammed, H., Miremadi, A. et al. TRPS1 regulates oestrogen receptor binding and histone acetylation at enhancers. Oncogene 37, 5281–5291 (2018). https://doi.org/10.1038/s41388-018-0312-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41388-018-0312-2

This article is cited by

Search

Advanced search

Quick links